Table 1.
Correlation between CTC levels and clinicopathological features of the melanoma patients.
| Clinicopathological features | Low CTC patients # | High CTC patients # | P value | |
|---|---|---|---|---|
| Age | <45 (%) | 25 (43.9) | 25 (58.1) | 0.157 |
| ≥45 (%) | 32 (56.1) | 18 (41.9) | ||
| Gender | Female (%) | 23 (40.4) | 15 (34.9) | 0.577 |
| Male (%) | 34 (59.6) | 28 (65.1) | ||
| Histology type | ALM (%) | 42 (73.7) | 30 (63.8) | 0.666 |
| Other (%) | 15 (26.3) | 13 (30.2) | ||
| S100B (μg/L) | <0.19 (%) | 30 (52.6) | 20 (46.5) | 0.545 |
| ≥0.19 (%) | 27 (47.3) | 23 (53.5) | ||
| Breslow thickness (mm) | <2.0 (%) | 42 (73.7) | 19 (44.2) | 0.003 |
| ≥2.0 (%) | 15 (26.3) | 24 (55.8) | ||
| Ulceration | No (%) | 42 (73.7) | 21 (48.8) | 0.011 |
| Yes (%) | 15 (26.3) | 22 (51.2) | ||
| N stage | N0/Nx (%) | 36 (63.2) | 35 (81.4) | 0.047 |
| N1+ (%) | 21 (36.8) | 8 (18.6) | ||
| M stage | No (%) | 36 (63.2) | 18 (41.8) | 0.034 |
| Yes (%) | 21 (36.8) | 25 (58.1) | ||
| TNM stage | I–II (%) | 35 (61.4) | 16 (37.2) | 0.017 |
| III–IV (%) | 22 (38.6) | 27 (62.8) | ||
| Outcome | Survived (%) | 25 (43.8) | 6 (14.0) | 0.001 |
| Died (%) | 32 (56.1) | 37 (86.0) | ||
| IFN alpha treatment | Yes (%) | 40 (70.2) | 35 (81.4) | 0.20 |
| No (%) | 17 (29.8) | 8 (18.6) | ||
ALM – acral lentiginous meloanoma.